CO6280050A1 - PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION - Google Patents

PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION

Info

Publication number
CO6280050A1
CO6280050A1 CO10068719A CO10068719A CO6280050A1 CO 6280050 A1 CO6280050 A1 CO 6280050A1 CO 10068719 A CO10068719 A CO 10068719A CO 10068719 A CO10068719 A CO 10068719A CO 6280050 A1 CO6280050 A1 CO 6280050A1
Authority
CO
Colombia
Prior art keywords
pharmaceutical form
phosphodesterase
inhibitors
relates
present
Prior art date
Application number
CO10068719A
Other languages
Spanish (es)
Inventor
Ovalle Jorge Hernando Useche
Zuniga Rafael Martinez
Zarta Cristina Salazar
Original Assignee
Sante S A Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sante S A Lab filed Critical Sante S A Lab
Priority to CO10068719A priority Critical patent/CO6280050A1/en
Publication of CO6280050A1 publication Critical patent/CO6280050A1/en
Priority to PCT/IB2011/001415 priority patent/WO2011154830A2/en
Priority to MX2012014237A priority patent/MX2012014237A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

La presente invención se refiere a una nueva forma farmacéutica de INHIBIDORES DE LA FOSFODIESTERASA para administración transmucosa. Más particularmente, la presente invención se refiere a unanueva composición farmacéutica líquida de tipo liposomal de INHIBIDORES DE LA FOSFODIESTERASA que contiene citrato de 1 - ((3 - (6,7-dihidro-1-metil-7-oxo-3-propil-1H-pirazolo (4,3-d) pirimidin-5-il)-4-etoxifenil)sulfonil)- 4-metilpiperazina, como agente activo asociado con uno o más excipientes farmacéuticamente aceptables.The present invention relates to a new pharmaceutical form of PHOSPHODIESTERASE INHIBITORS for transmucosal administration. More particularly, the present invention relates to a new liquid pharmaceutical composition of the liposomal type of PHOSPHODIESTERASE INHIBITORS containing 1 - ((3 - (6,7-dihydro-1-methyl-7-oxo-3-propyl-) citrate 1H-pyrazolo (4,3-d) pyrimidin-5-yl) -4-ethoxyphenyl) sulfonyl) -4-methylpiperazine, as an active agent associated with one or more pharmaceutically acceptable excipients.

CO10068719A 2010-06-08 2010-06-08 PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION CO6280050A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CO10068719A CO6280050A1 (en) 2010-06-08 2010-06-08 PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION
PCT/IB2011/001415 WO2011154830A2 (en) 2010-06-08 2011-06-03 Pharmaceutical form comprising phosphodiesterase inhibitors, for transmucosal administration
MX2012014237A MX2012014237A (en) 2010-06-08 2011-06-03 Pharmaceutical form comprising phosphodiesterase inhibitors, for transmucosal administration.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CO10068719A CO6280050A1 (en) 2010-06-08 2010-06-08 PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION

Publications (1)

Publication Number Publication Date
CO6280050A1 true CO6280050A1 (en) 2011-05-20

Family

ID=44084021

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10068719A CO6280050A1 (en) 2010-06-08 2010-06-08 PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION

Country Status (3)

Country Link
CO (1) CO6280050A1 (en)
MX (1) MX2012014237A (en)
WO (1) WO2011154830A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
DK1802277T3 (en) * 2004-10-18 2010-05-17 Polymun Scient Immunbio Forsch Liposomal composition containing an active ingredient for relaxation of smooth muscle and therapeutic use of the composition
CN101269212B (en) * 2008-04-30 2013-09-18 上海麟翔生物技术有限公司 Gargle capable of being swallowed

Also Published As

Publication number Publication date
MX2012014237A (en) 2013-01-18
WO2011154830A2 (en) 2011-12-15
WO2011154830A3 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
NI201600058A (en) RING-FUSED BICYCLIC PYRIDYL-DERIVED COMPOUNDS AS FGFR4 INHIBITORS
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
UY33536A (en) BICYCLIC INHIBITORS OF ACETIL-CoA-CARBOXYLASE AND USES OF THE SAME
UY35663A (en) DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF COMPLEMENT FACTOR B AND USES OF THE SAME
BR112015000229A2 (en) stable aqueous formulations of etanercept
CU20160192A7 (en) INDANO AND INDOLINA DERIVATIVES USEFUL AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
UY32816A (en) PHARMACEUTICAL FORMULATION BASED ON 1- [2- (2,1,3-BENZOTIADIAZOL-5-ILAMINO) -6 (2,6-DICLOROFENIL) -PIRIDO [2,3-D] PIRIMIDIN-7-IL] -3- TERT-BUTIL-URÉA
EA201100358A1 (en) DABIGATRAN FOR INTERTEGUAL SURGICAL CATHETERIZATION OF THE HEART
DOP2015000170A (en) CHEMICAL COMPOUNDS
CR20140508A (en) MODULATORS OF THE ROUTE OF THE COMPLEMENT AND USES OF THE SAME
CU20150084A7 (en) ACID DERIVATIVES 4 - ((1,1) BISFENIL -4-IL) -3- (3-PHOSPHONOPROPANAMIDE) BUTANOIC, ACTIVE AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE)
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
CY1118032T1 (en) PROCESSES FOR COMMERCIAL PREPARATION OF PHARMACEUTICAL ACTIVE AGENT
UY33348A (en) FUROPIRIDINE COMPOUNDS AND USES OF THE SAME
MX2015007940A (en) Tricyclic compounds as cftr inhibitors.
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
MX2016006667A (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors.
BR112015023078A2 (en) pyrrolopyrimindine cdk9 kinase inhibitors
CO6280050A1 (en) PHARMACEUTICAL FORM OF PHOSPHODESTERASE INHIBITORS FOR TRANSMUCOUS ADMINISTRATION
PE20150022A1 (en) DRONEDARONE FOR USE IN LEISHMANIOSIS, FORMULATIONS AND ASSOCIATIONS FOR USE IN LEISHMANIOSIS
EA201500366A1 (en) APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR
UY33857A (en) THIOPHENE COMPOUNDS 2,3,5-TRISUSTITUIDOS AND USES OF THE SAME.

Legal Events

Date Code Title Description
FC Application refused